Erez M, Shtacher G, Weinstock M
J Med Chem. 1978 Sep;21(9):982-4. doi: 10.1021/jm00207a025.
The relationship between molecular structure and cardioselectivity is described in the 1-(para-substituted aryl-oxy)-3-(isoprophylamino)propan-2-ol type of beta-adrenoceptor blocking agents. Cardioselectivity in the aforementioned series requires that the aromatic substitution in the position para to the amino alcohol side chain will have a minimal linear length of 5.0 A. Highest cardioselectivity is obtained when this para substituent is a rigid group coplanar with the aromatic ring. This may result from steric hindrance for binding at the beta2-adrenoceptor subtype which does not occur in the beta1 subtype. Evidence in favor of this suggestion was obtained by the finding that the trans isomer of 1-[4-(1-propenyl)-2-methoxyphenoxy]-3-(isopropylamino)propan-2-ol is cardioselective (beta1/beta2 = 25), whereas the cis isomer is beta2 selective (beta1/beta2 = 0.1).
在1 - (对 - 取代芳氧基) - 3 - (异丙基氨基)丙 - 2 - 醇类β - 肾上腺素能受体阻滞剂中描述了分子结构与心脏选择性之间的关系。上述系列中的心脏选择性要求氨基醇侧链对位的芳族取代基的最小线性长度为5.0埃。当该对位取代基是与芳环共面的刚性基团时,可获得最高的心脏选择性。这可能是由于在β2 - 肾上腺素能受体亚型上结合时存在空间位阻,而在β1亚型中不存在这种情况。通过发现1 - [4 - (1 - 丙烯基) - 2 - 甲氧基苯氧基] - 3 - (异丙基氨基)丙 - 2 - 醇的反式异构体具有心脏选择性(β1/β2 = 25),而顺式异构体具有β2选择性(β1/β2 = 0.1),获得了支持该建议的证据。